What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

To compare outcomes of low-intensity AML therapy based on treatment facility focusing on molecular mutations.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows no OS difference for AML treatment at academic versus community facilities, indicating TP53 mutations worsen outcomes.

To compare outcomes of low-intensity AML therapy based on treatment facility focusing on molecular mutations.
Conducted a retrospective single-center analysis of patients with AML treated with low-intensity therapy.
Categorized patients into groups based on treatment facility: academic center vs collaborative/community center.
Utilized various statistical analyses including Cox and logistic regression to evaluate OS and treatment response.
Among 135 patients, no significant OS difference found between academic and community groups.
TP53 mutations were linked to worse overall survival, increasing death risk by 73%.
Patients with NPM1 mutations had better response rates but similar OS compared to the overall AML population.

Larson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows no OS difference for AML treatment at academic versus community facilities, indicating TP53 mutations worsen outcomes.